AstraZeneca is a global science-led biopharmaceutical company with strong UK and Swedish roots that focuses on prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular- Renal - Metabolism, and Respiratory. AstraZeneca operates in over 100 countries with headquarters in UK and Sweden and our innovative medicines are used by millions of patients worldwide. In 2018, AstraZeneca invested USD 6.1 billion in our science . We have 3 main strategic R&D Centers in Cambridge - UK, Gaithersburg – Maryland, US, and Gothenburg - Sweden where collaborative, innovative and dynamic environment allows our scientists to keep pushing the boundaries of science. Our leading position in the investment in clinical research in Vietnam echoes our commitment to bring scientific innovations to patients. AstraZeneca is proud of our 25 years journey in Vietnam as we have been working with the Government and partners to protect and promote the health and wellbeing of Vietnamese citizens, and contribute to the country’s healthcare system development. AstraZeneca received Viet Nam Health Minister’s Award for outstanding contribution in cancer prevention and treatment, contributing to the development of Vietnam healthcare in 2019. Our leading position in the investment in clinical research in Vietnam echoes our commitment to bring scientific innovations to patients. AstraZeneca Vietnam was established in 2018 and has received licence for drug import and export and approval for clinical trials activities from Vietnam’s Ministry of Health in Nov 2019.
Mr. Nitin Kapoor
Chief Representative & General Manager
Mr. Thien Pham
Head of Corporate Affairs & Public Policy, Vietnam
Ms. Nhung Tuyet Thi Tran
Head of Human Resources, Vietnam and Frontier Markets